Cancer Mucosa Antigens as a Novel Immunotherapeutic Class of Tumor‐associated Antigen | Zendy

Snook A E | Zendy; Eisenlohr L C | Zendy; Rothstein J L | Zendy; Waldman S A | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Cancer Mucosa Antigens as a Novel Immunotherapeutic Class of Tumor‐associated Antigen

Author(s) -

Snook A E,

Eisenlohr L C,

Rothstein J L,

Waldman S A

Publication year - 2007

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/sj.clpt.6100369

Subject(s) - antigen , medicine , colorectal cancer , context (archaeology) , immunotherapy , immune system , cancer , immunology , cancer immunotherapy , clinical pharmacology , disease , cancer research , biology , pharmacology , paleontology

Colorectal cancer is a leading cause of cancer‐related mortality worldwide. Surgery and chemoradiation exhibit incomplete efficacy and, ultimately, 50% of patients die of metastatic disease. In the context of that unmet clinical need, immunotherapeutic approaches have enjoyed limited success, partly because of a paucity of suitable antigen targets. However, exploitation of immune compartmentalization, employing antigens with expression restricted to normal intestinal mucosa and derivative colorectal tumors—cancer mucosa antigens (CMAs)—may represent a previously unrecognized class of immune targets supporting efficacious antitumor immunotherapy. Guanylyl cyclase C (GCC) is an intestine/colorectal cancer‐restricted protein ideally suited as the first CMA for clinical evaluation. Clinical Pharmacology & Therapeutics (2007) 82 , 734–739. doi: 10.1038/sj.clpt.6100369 ; published online 26 September 2007

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research